Breshly News

Mandolin, a platform that makes use of AI automation to boost entry to specialty medicine, has introduced it secured $40 million in funding. 

Maverick, SignalFire, SV Angel, Greylock Companions, Jerry Yang (cofounder of Yahoo) and Guillermo Rauch (CEO of Vercel) participated within the spherical.

WHAT IT DOES

Mandolin presents an AI-enabled workflow automation platform to be used within the administrative aspect of specialty medicine. Its AI brokers help with consumption, prior authorizations, advantages and income cycle administration. 

The San Francisco-based firm says its platform integrates into EHRs, producer hubs and payer portals.

Mandolin launched its product in January and touts that it’s deployed in additional than 700 scientific areas.

“We’ll use this capital to develop the staff, primarily specializing in world-class engineering and buyer implementation expertise as a way to extra deeply serve the wants of our refined clients,” Will Yin, cofounder and CEO of Mandolin, informed MobiHealthNews in an electronic mail.

MARKET SNAPSHOT

Whole spending on specialty medicine elevated from 21.7% in 2012 to 71.1% in 2021, based on a research printed within the Journal of Managed Care and Specialty Pharmacy. Specialty medicine accounted for six.2% of prescriptions however 71.1% of complete spending in 2021.

Different digital well being corporations working within the specialty drug house embrace Serve You Rx, a pharmacy profit supervisor, which in Could introduced a collaboration with Amazon Pharmacy to supply house supply providers for upkeep medicine to its members.

Serve You Rx members can entry frequent medicines, and specialty sufferers can use Waltz Well being’s AI-powered platform to entry their specialty medicine.

In April, Mark Cuban Price Plus Medicine introduced a collaboration with specialty pharmaceutical distributor Morris & Dickson to offer entry to injectable medicines through the Price Plus Market.

California-based SamaCare presents a workflow platform for suppliers providing specialty medicine. Final yr, the corporate secured $17 million in an oversubscribed Sequence B funding spherical.